Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-88549968 |
| Synonyms | |
| Therapy Description |
JNJ-88549968 is a bispecific antibody that targets CALR mutations and CD3, which potentially induces an immune response against tumor cells with CALR mutations and inhibits tumor growth (Blood (2023) 142 (Supplement 1): 1777). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-88549968 | JNJ88549968|JNJ 88549968 | CD3 Antibody 119 | JNJ-88549968 is a bispecific antibody that targets CALR mutations and CD3, which potentially induces an immune response against tumor cells with CALR mutations and inhibits tumor growth (Blood (2023) 142 (Supplement 1): 1777). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06150157 | Phase I | JNJ-88549968 | A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | Recruiting | USA | ITA | ISR | GBR | FRA | ESP | DEU | CAN | 0 |